'Severe' geomagnetic storm could spread Northern Lights south to California, Alabama Sunday night
A "severe" geomagnetic storm may be brewing early next week, and many Americans across the nation – perhaps even as far as the Deep South – may be treated to a rare display of the Northern Lights, according to NOAA's Space Weather Prediction Center.
A powerful coronal mass ejection (CME), which is a burst of solar material and magnetic fields from the Sun, erupted on Friday night, triggering a Severe Geomagnetic Storm Watch, the SWPC said.
What Is A Geomagnetic Storm?
The CME will reach Earth on Sunday, when it is expected to produce geomagnetic storms causing disruptions to the planet's magnetosphere.
The SWPC issued a level G3 out of 5 (Strong) Geomagnetic Storm Watch for Sunday, and upgraded it to a level G4 (Severe) Geomagnetic Storm Watch for Sunday night into early Monday morning.
There is even a chance the storm could reach "Extreme" G5 levels, which were the levels reached during the epic event on May 10, 2024, that spread the Northern Lights to Florida and the Caribbean, according to the SWPC.
What Are The 5 Categories That Measure Geomagnetic Storms?
While strong geomagnetic storms are harmless to human health, potential impacts include widespread problems with voltage control, along with some issues with the power grid. Additionally, spacecraft may see problems, such as low Earth orbit satellites experiencing increased drag. High-frequency radio signals may be disrupted.
On the aesthetic side of things, the geomagnetic storm is expected to produce an aurora that will be visible over much of the northern half of the U.s., with some of the displays potentially dipping down as far south as Alabama and northern California.
The forecast looks favorable across much of the U.S., and even in the South except for the Desert Southwest, where remnants of Tropical Storm Alvin are bringing clouds and storms.
How To Watch Fox Weather
Impacts will lessen come Tuesday, when the geomagnetic storm levels are expected to subside.Original article source: 'Severe' geomagnetic storm could spread Northern Lights south to California, Alabama Sunday night
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
34 minutes ago
- Associated Press
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in The Lancet.1 In a phase 1b/2a clinical trial of 125 adults with overweight or obesity, once-weekly subcutaneous amycretin appeared to be safe and tolerable in trial participants, who also achieved significantly greater weight loss across the full range of doses investigated versus placebo.1 A related phase 1 trial of once-daily oral amycretin in adults with obesity or overweight also showed that treatment was safe and tolerable with an observed reduction in body weight compared to placebo.2 No weight loss plateau was observed in either trial at the end of the respective treatment durations.1,2 Data on subcutaneous amycretin is scheduled to be presented on Sunday, June 22nd, during a late-breaking poster session at the American Diabetes Association's® (ADA) 85th Scientific Sessions.1 'We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management. At Novo Nordisk, we understand that addressing obesity is a complex challenge that many patients face. These results reflect our robust pipeline in obesity, our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk. 'We remain steadfast in our mission to discover and develop therapies that can have a meaningful impact in the lives of those affected by obesity.' Results from the phase 1b/2a trial of subcutaneous amycretin showed treatment-emergent adverse events (TEAEs) were mild or moderate in severity and increased in frequency in a dose-dependent manner. The most frequent reported TEAEs were gastrointestinal in nature. Compared to placebo, participants receiving amycretin observed greater weight loss across the full range of doses investigated.1 Subcutaneous amycretin at multiple doses demonstrated greater weight reduction than placebo at the end of the trial. Participants who received the highest doses (up to 60 mg) reported body weight reductions of up to 24.3% versus 1.1% with placebo after 36 weeks of treatment. Results from this first-in-human phase 1b/2a study support further investigation of potential weight-loss efficacy of amycretin. Results from the published phase 1 trial of oral amycretin showed that the most common TEAEs were related to gastrointestinal symptoms (mainly nausea and vomiting) and decreased appetite; these were most frequent for the higher doses. Trial participants receiving the study treatment demonstrated significantly greater weight loss across the full range of doses investigated versus the placebo group.2 Exploratory results showed participants taking 100 mg per day of oral amycretin achieved a mean weight loss of 13.1% versus 1.2% with placebo after 12 weeks.2 Based on these phase 1 results, longer evaluation with more participants is warranted to substantiate the full efficacy findings of oral amycretin on body weight reductions and changes in metabolic parameters. Novo Nordisk will advance both subcutaneous and oral amycretin formulations straight to phase 3 development for weight management based on these and other completed clinical studies, as well as feedback received from regulatory authorities. About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is under investigation for oral and subcutaneous administration, and is not approved in the US for weight loss. About the phase 1b/2a subcutaneous amycretin trial The phase 1b/2a trial was a randomized, placebo-controlled, single-center, double-blinded study of 125 participants assessing the safety, tolerability, pharmacokinetics, and effects on body weight after subcutaneous administration of amycretin in people with overweight or obesity.1 Adults with a body mass index of 27-39.9kg/m2 and glycated hemoglobin (HbA1c) <6.5% were eligible for the trial.1 The trial was conducted in 5 parts: a single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B).1 Lastly, in the multiple ascending dose – dose response parts, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).1 About the phase 1 oral amycretin trial The phase 1 single-center, randomized, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (Part A) and multiple ascending doses (Part B, 10 days of treatment; Part C/D, 12 weeks of treatment) of 144 adult participants with overweight or obesity.2 The primary endpoint was the number of treatment-emergent adverse events (TEAEs) observed in the trial. The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.2 About obesity Obesity is a serious chronic, progressive, and complex disease that requires long-term management.3-5 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.3,5 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.6,7 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.8,9 In the US, about 40% of adults live with obesity.10 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information References © 2025 Novo Nordisk All rights reserved. US25SEMO01477 June 2025 View original content to download multimedia: SOURCE NOVO NORDISK INC.
Associated Press
34 minutes ago
- Associated Press
MountBay Energy Unlocks Microbial Biofilm Technology to Revolutionize Battery Longevity
NEW YORK, June 21, 2025 (GLOBE NEWSWIRE) -- MountBay Energy has unveiled groundbreaking research on microbial biofilms that could redefine the future of grid-scale energy storage. The study, led by founder Vrushabhraj Tanawade, introduces a bio-integrated insulation method using thermophilic and mesophilic microbial consortia to regulate heat inside battery modules. The results are striking: up to a 22% reduction in internal temperature and a 30% improvement in carbon lifecycle efficiency. 'This innovation is about biology meeting infrastructure,' says Tanawade. 'We've discovered how nature's mechanisms can dramatically extend the life of our clean energy systems.' Unlike conventional synthetic cooling solutions, MountBay's microbial approach is circular, biodegradable, and scalable—opening up new frontiers for climate resilience and fire-risk reduction in hot environments. The research aligns perfectly with MountBay's mission to power the AI economy through clean, sustainable, and advanced infrastructure. It also positions the company as a frontrunner in biological material integration across the energy sector. Additionally, MountBay has released a preliminary transformative feasibility report for a Lunar Solar Belt—a continuous solar array on the Moon that can beam uninterrupted, clean energy back to Earth. The report outlines how in-situ resource utilization (ISRU), autonomous lunar robotics, and microwave power transmission could enable the construction of a moon-based solar plant by the 2030s. With an energy return on investment (EROI) of 8:1, the system offers a scalable, emission-free solution to humanity's growing power demands. 'This is not just an energy project—it's a civilization-scale investment in global stability,' said Tanawade. 'We believe the Moon should be a cooperative utility, not a geopolitical race.' MountBay is also proposing a new diplomatic framework—The Earth-Moon Energy Accord (EMEA)—to ensure equitable access, safety, and international cooperation. The concept directly supports MountBay's mission: to push the frontiers of clean power while securing energy independence for AI-driven economies. Tanawade is rallying governments, institutions, and innovators to join him. 'It's time for America to lead the most ambitious energy project in human history,' he said. Media Contact: Vrushabhraj Tanawade Founder @ MountBay Energy Contact : [email protected] Website: Linkedin: Linkedin - Vrushabhraj T Disclaimer: This press release is provided by MountBay Energy. The statements, views, and opinions expressed are solely those of the provider and do not necessarily reflect those of this media platform or its publisher. Any names or brands mentioned are used for identification purposes only and remain the property of their respective owners. No endorsement or guarantee is made regarding the accuracy, completeness, or reliability of the information presented. This material is for informational purposes only and does not constitute financial, legal, or professional advice. Readers are encouraged to conduct independent research and consult qualified professionals. The publisher is not liable for any losses, damages, or legal issues arising from the use or publication of this content. Photos accompanying this announcement are available at:
Yahoo
44 minutes ago
- Yahoo
Woman Says She Will No Longer Participate in Her Boyfriend's Family Events After Several Slights: ‘I Don't Feel Welcome'
A woman shared on Reddit that she and her boyfriend have been kept at a distance by his family The woman was upset that her boyfriend's sister-in-law didn't postpone her pregnancy announcement for a few days so that the couple could be present The woman now refuses to attend any family events due to feeling slightedA woman claims her boyfriend's family has kept her at a distance — and now she doesn't want to have anything to do with them. In a post on Reddit's "Am I the A------" forum, the 31-year-old woman detailed her fractured relationship with her boyfriend's family. The couple has been together for almost three years, and in the beginning, his family members 'were kind and really put in effort to get to know me," the OP (original poster) said. "His sister (27F) and his sister-in-law (29F) would text me to plan dinner together, we'd work out together, etc. The feeling was mutual," she continued. But then things began to change. 'Slowly, I've noticed them both distancing themselves from me with no apparent reason to my knowledge,' she wrote. According to the OP, her boyfriend's brother once reached out to ask if the couple wanted to go to Hawaii with him and his wife. The OP and her boyfriend took a few hours to consider and then said yes. 'His brother responds back saying 'never mind, we decided to go with a smaller group' essentially just removing us since everyone else was still going,' she claimed. 'They went on their trip and blocked me and my bf from seeing their social media stories (to this day we're still blocked but haven't spoken up about it to them). There was never an apology or an attempt to communicate what happened, it was just swept under the rug.' The OP also mentioned another incident in which the family had texted them to come over on a Thursday night. She and her boyfriend couldn't attend, but told the family they would see them that Sunday, which was Father's Day. 'The sister texts us a video that night that the SIL/brother are announcing their first pregnancy and that we missed it," she wrote. "There was no attempt to reschedule the announcement so that we could all be present for it. They could've easily said the news on Father's Day, just days later.' Feeling upset and slighted, the woman had a conversation with her boyfriend and expressed her 'concerns that his family is making it clear they don't value our presence." "Whenever we go over to the family home, it feels like everyone goes quiet and dilutes their personality until we leave," she noted. The conversation ended with the OP telling her boyfriend that she will no longer attend his family's events, nor will she congratulate the sister-in-law on her pregnancy due to her "standoffish" behavior. 'I will not go where I don't feel welcome. Today he went to the family home alone and I stayed at home," the OP finished her post, asking fellow Redditors, "AITA [am I the a------]?" For many users, the answer was a resounding yes. Some suggested that she was wrongly perceiving certain situations as slights. 'You can't expect someone to postpone their pregnancy announcement — they invited you, and they shared the video afterwards," one person wrote. "They are allowed to keep that separate from Father's Day, and to share the information with people separately. And refusing to congratulate his SIL is just churlish. It is almost always better to build bridges than burn them." Others questioned whether the woman was leaving facts out of her post to explain why there is a perceived distance between her and the boyfriend's family. 'This sounds a bit like a situation where there are missing reasons somewhere,' a reader said. 'The expectation that they postpone pregnancy announcement is too much." The same reader suspected that the family 'slowly distanced themselves for some reasons you are choosing to not analyze.' However, other commenters sympathized with the OP — particularly regarding the Hawaii invite that was rescinded — and encouraged a direct conversation. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. 'I'd want closure, and if I have to make family dinner awkward for everyone to get that closure, I will,' one person wrote. 'Then let them know that since they don't see you as family, that you will not be treating them as such and simply cut them off.' Read the original article on People
